Simultaneous point-of-care testing of blood lipid profile and glucose: Performance evaluation of the GCare Lipid Analyzer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ha Nui | - |
dc.contributor.author | Yoon, Soo-Young | - |
dc.date.accessioned | 2022-04-29T04:40:26Z | - |
dc.date.available | 2022-04-29T04:40:26Z | - |
dc.date.created | 2022-04-28 | - |
dc.date.issued | 2021-12 | - |
dc.identifier.issn | 0887-8013 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/140520 | - |
dc.description.abstract | Background Point-of-care (POC) testing provides quick results and includes tests for blood glucose and lipid profiles. We evaluated the newly developed POC device, the GCare Lipid Analyzer, which is used to measure glucose, total cholesterol (TC), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) levels. Methods Venous and capillary blood samples were collected from patients who visited Korea University Guro Hospital. The results obtained using the GCare Lipid Analyzer were compared with those obtained using the TBA 2000FR chemistry analyzer and YSI 2300 STAT Plus analyzer. The glucose system evaluation process was based on the International Organization for Standardization 15197:2013 guidelines. Results The correlation coefficients (R) for TC, TG, and HDL-C were 0.965, 0.969, and 0.943 in capillary blood and 0.969, 0.990, and 0.956 in venous blood, respectively. The total errors for TC, TG, and HDL-C of the lipid profile using venous blood were all acceptable at 6.6%, 9.3%, and 11.6%, respectively. For glucose concentrations <100 mg/dl, 96.1% of the measured glucose levels were within +/- 15 mg/dl in venous samples and 100% were within +/- 15 mg/dl in capillary samples. For glucose concentrations >= 100 mg/dl, 100% and 99.5% of the measured glucose levels were within 15% for venous and capillary blood, respectively. Conclusion The performance of the GCare Lipid Analyzer is acceptable for both blood glucose and lipid profile testing, indicating that it is reliable for use in patients with diabetic dyslipidemia. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | EDUCATION-PROGRAM RECOMMENDATIONS | - |
dc.subject | DENSITY-LIPOPROTEIN CHOLESTEROL | - |
dc.title | Simultaneous point-of-care testing of blood lipid profile and glucose: Performance evaluation of the GCare Lipid Analyzer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Soo-Young | - |
dc.identifier.doi | 10.1002/jcla.24055 | - |
dc.identifier.scopusid | 2-s2.0-85118158523 | - |
dc.identifier.wosid | 000710781900001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL LABORATORY ANALYSIS, v.35, no.12 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL LABORATORY ANALYSIS | - |
dc.citation.title | JOURNAL OF CLINICAL LABORATORY ANALYSIS | - |
dc.citation.volume | 35 | - |
dc.citation.number | 12 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Medical Laboratory Technology | - |
dc.relation.journalWebOfScienceCategory | Medical Laboratory Technology | - |
dc.subject.keywordPlus | EDUCATION-PROGRAM RECOMMENDATIONS | - |
dc.subject.keywordPlus | DENSITY-LIPOPROTEIN CHOLESTEROL | - |
dc.subject.keywordAuthor | diabetes mellitus | - |
dc.subject.keywordAuthor | dyslipidemia | - |
dc.subject.keywordAuthor | glucose | - |
dc.subject.keywordAuthor | lipid | - |
dc.subject.keywordAuthor | POC | - |
dc.subject.keywordAuthor | point-of-care testing | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.